Executive summary: Based on a broad survey of clinical and observational research, this evidence-based analysis concludes that reduced risk tobacco products—particularly e-cigarettes and snus—are at least as effective, and often more effective at a population level, than other cessation methods for helping smokers quit, supporting their role as a viable tool in tobacco harm reduction strategies.
Key points:
Comparative effectiveness: Randomized controlled trials show that nicotine vapes are about 50% more effective than nicotine replacement therapy (NRT), and similarly effective to pharmaceutical aids like varenicline.
Population-level impact: Observational data from countries like Sweden, Norway, England, and Japan show significant smoking reductions associated with increased availability and use of noncombustible products, often surpassing the impact of conventional cessation tools.
User preference and uptake: Noncombustibles, particularly vapes, are far more commonly used than traditional methods, leading to greater absolute numbers of successful quitters despite similar per-attempt effectiveness.
Limitations of existing methods: Unassisted quitting remains the most common but least effective method, while pharmaceutical and behavioral interventions show limited effectiveness and adoption, especially outside clinical settings.
Causal uncertainty and correlation caveats: While real-world data are compelling, causal claims are limited by the observational nature of most studies and potential confounding factors.
Implication for effective altruism: The evidence suggests that concerns about the effectiveness of reduced risk products should not be a major obstacle to considering tobacco harm reduction a high-impact cause area.
This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, and contact us if you have feedback.
Executive summary: Based on a broad survey of clinical and observational research, this evidence-based analysis concludes that reduced risk tobacco products—particularly e-cigarettes and snus—are at least as effective, and often more effective at a population level, than other cessation methods for helping smokers quit, supporting their role as a viable tool in tobacco harm reduction strategies.
Key points:
Comparative effectiveness: Randomized controlled trials show that nicotine vapes are about 50% more effective than nicotine replacement therapy (NRT), and similarly effective to pharmaceutical aids like varenicline.
Population-level impact: Observational data from countries like Sweden, Norway, England, and Japan show significant smoking reductions associated with increased availability and use of noncombustible products, often surpassing the impact of conventional cessation tools.
User preference and uptake: Noncombustibles, particularly vapes, are far more commonly used than traditional methods, leading to greater absolute numbers of successful quitters despite similar per-attempt effectiveness.
Limitations of existing methods: Unassisted quitting remains the most common but least effective method, while pharmaceutical and behavioral interventions show limited effectiveness and adoption, especially outside clinical settings.
Causal uncertainty and correlation caveats: While real-world data are compelling, causal claims are limited by the observational nature of most studies and potential confounding factors.
Implication for effective altruism: The evidence suggests that concerns about the effectiveness of reduced risk products should not be a major obstacle to considering tobacco harm reduction a high-impact cause area.
This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, and contact us if you have feedback.